The leading Asia-Pacific biotech specialist CRO Novotech has been awarded a prestigious CRO Leadership Award by Life Science Leader magazine based on findings from sponsor companies that utilise outsourcing services.

In particular, Novotech was recognized for meeting or exceed their customer’s expectations. This is Novotech’s second award from Life Sciences Leader.

Sponsors provided ratings of CROs based on recent outsourced projects. 60 contract research organizations were assessed across multiple dimensions.

As part of a detailed review of the CRO industry from the biopharma perspective, Life Science Leader selected Novotech as a leader in a number of key categories including:

  1. Compatibility with biopharma companies
  2. Capabilities
  3. Quality
  4. Reliability

"When talking to clinical operations executives, I'm told the CRO selection process can be one of their most stressful and time-consuming chores," says Ed Miseta, chief editor, Clinical Leader.

"Anything we can do to help steer our readers to those partners that best meet their needs can significantly reduce the burden of their search. That is why we are once again proud to partner with Industry Standard Research to produce our annual CRO Leadership Awards.

The organizations being honored have proven themselves to be the top performers in Compatibility, Capabilities, Quality and Reliability. We applaud these companies for their hard work in meeting the needs and expectations of their pharma and biotech clients."

Novotech CEO Dr John Moller said he was pleased Novotech was recognized by the biotech industry for its expertise in the Asia-Pacific.

There is nothing better than having sponsors recommend Novotech across the core dimensions required to deliver clinical trials.”

Dr Moller added “Novotech is continuing to grow strongly in the region, with most Asia Pacific countries emerging from the COVID-19 crisis and the majority of sites operating normally.

Other relevant content